Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.

Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.

OBJECTIVE: To assess the feasibility and impact of highly active antiretroviral therapy (HAART) started in vertically HIV-1-infected infants less than 3 months of age. DESIGN: A multicentre, phase I/II, non-randomized, open-label study (PENTA 7). METHODS: Adverse events, plasma HIV-1 RNA, CD4 cell...

Podrobná bibliografie
Hlavní autoři:	Aboulker, J, Babiker, A, Chaix, M, Compagnucci, A, Darbyshire, J, Debré, M, Faye, A, Giaquinto, C, Gibb, D, Harper, L, Saïdi, Y, Walker, A
Médium:	Journal article
Jazyk:	English
Vydáno:	2004

Podobné jednotky

Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial
Autor: Aboulker, J, a další
Vydáno: (2002)

Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life
Autor: Barbara Laughton, a další
Vydáno: (2019-10-01)

A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial.
Autor: Green, H, a další
Vydáno: (2006)

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
Autor: Walker, A, a další
Vydáno: (2010)

Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution.
Autor: Lewis, J, a další
Vydáno: (2012)

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
Autor: Babiker, A, a další
Vydáno: (2011)

Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
Autor: Keene, CM, a další
Vydáno: (2023)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Autor: Munderi, P, a další
Vydáno: (2010)

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
Autor: Gibb, D, a další
Vydáno: (2002)

When should children with HIV infection be started on antiretroviral therapy?
Autor: Steven B Welch, a další
Vydáno: (2008-03-01)

Monitoring of highly active antiretroviral therapy in HIV infection.
Autor: Walker, A, a další
Vydáno: (2011)

The impact of different CD4 cell-count monitoring and switching strategies on mortality in HIV-infected African adults on antiretroviral therapy: an application of dynamic marginal structural models
Autor: Ford, D, a další
Vydáno: (2015)

The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.
Autor: Ford, D, a další
Vydáno: (2015)

Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters.
Autor: Babiker, A, a další
Vydáno: (2003)

Immediate start of antiretroviral, why not?
Autor: Elaine Monteiro Matsuda, a další

Getting started with Google Apps /
Autor: 192197 Darbyshire, Paul, a další
Vydáno: (c201)

Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial
Autor: Post, F, a další
Vydáno: (2018)

Thymic Output and CD4 T-Cell Reconstitution in HIV-Infected Children on Early and Interrupted Antiretroviral Treatment: Evidence from the Children with HIV Early Antiretroviral Therapy Trial
Autor: Lewis, J, a další
Vydáno: (2017)

Analysis of multivariate failure-time data from HIV clinical trials.
Autor: Walker, A, a další
Vydáno: (2000)

Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era
Autor: Beral, V, a další
Vydáno: (2004)

Issues in the design and analysis of therapeutic trials in human immunodeficiency virus infection
Autor: Babiker, A, a další
Vydáno: (1998)

Markers of HIV infection in the Concorde trial. Concorde Co-ordinating Committee.
Autor: Walker, A, a další
Vydáno: (1998)

Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy.
Autor: Buclin, T, a další
Vydáno: (2011)

Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
Autor: Gilks, C, a další
Vydáno: (2012)

When to start antiretroviral therapy in infants and children
Autor: Mark F Cotton, a další
Vydáno: (2009-12-01)

Randomization-based methods for correcting for treatment changes: examples from the Concorde trial.
Autor: White, I, a další
Vydáno: (1999)

Impact of treatment changes on the interpretation of the Concorde trial.
Autor: White, I, a další
Vydáno: (1997)

Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.
Autor: Picat, M, a další
Vydáno: (2013)

Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe
Autor: Lara, A, a další
Vydáno: (2012)

Rapid antiretroviral therapy initiation in low- and middle-income countries: A resource-based approach
Autor: Tenforde, M, a další
Vydáno: (2019)

Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study.
Autor: Walker, A, a další
Vydáno: (2004)

When to start antiretroviral therapy in HIV-associated tuberculosis.
Autor: Török, M, a další
Vydáno: (2011)

Active cytomegalovirus retinitis after the start of antiretroviral therapy
Autor: Heiden, D, a další
Vydáno: (2018)

When to start antiretroviral therapy in HIV-infected children
Autor: Tammy Meyers
Vydáno: (2002-07-01)

Biphasic decay of cell-associated HIV-1 DNA in HIV-1-infected children on antiretroviral therapy.
Autor: De Rossi, A, a další
Vydáno: (2002)

Age as a determinant of survival in HIV infection.
Autor: Babiker, A, a další
Vydáno: (2001)

Start to finish : 24 weeks to an endurance triathlon /
Autor: 392625 Huddle, Paul, a další
Vydáno: (2004)

Weekly, monthly and seasonal rainfall at Bengaluru in Karnataka
Autor: B.T. RAVINDRABABU, a další
Vydáno: (2010-12-01)

Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy.
Autor: Thierry Buclin, a další
Vydáno: (2011-01-01)

Same Week: Feasibility of Rapid Antiretroviral Initiation in Brazil
Autor: Elaine Monteiro Matsuda, a další
Vydáno: (2021-01-01)